<DOC>
	<DOCNO>NCT02342639</DOCNO>
	<brief_summary>The purpose study determine Rifaximin decrease serum urine level bacterial byproduct inflammatory marker patient chronic kidney disease evaluate change bacterial content stool individual .</brief_summary>
	<brief_title>Rifaximin Therapy Chronic Kidney Disease</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Rifaximin</mesh_term>
	<mesh_term>Rifamycins</mesh_term>
	<criteria>Chronic kidney disease eGFR â‰¤ 39 ml/min/1.73m2 Patients normal renal function less advanced kidney disease Inability unwillingness provide consent Patients undergoing hemodialysis peritoneal dialysis therapy undergone organ transplant Patients may pregnant Hemodynamically unstable patient Patients liver failure , pancreatic insufficiency , inflammatory bowel disease Patients ongoing recent infection history Cdiff infection Patients abnormal bowel structure secondary surgical anatomic variation Patients certain medication include immunosuppressant , antidiarrheal agent , bile acid sequestrants current recent ( within last 3 month ) use antibiotic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>